Compare PYXS & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PYXS | EOD |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.5M | 252.4M |
| IPO Year | 2021 | N/A |
| Metric | PYXS | EOD |
|---|---|---|
| Price | $4.24 | $5.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 683.6K | 118.1K |
| Earning Date | 11-03-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.28% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,820,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $3.73 |
| 52 Week High | $5.55 | $4.71 |
| Indicator | PYXS | EOD |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 68.59 |
| Support Level | $4.11 | $5.58 |
| Resistance Level | $4.35 | $5.89 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 32.98 | 100.00 |
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.